Alkermes (ALKS) Income from Continuing Operations (2010 - 2026)

Alkermes' (ALKS) quarterly Income from Continuing Operations came in at 66526000.0 in Q1 2026, down 395.82% year-on-year from 22489000.0 in Q1 2025, and down 168.87% on a QoQ basis from 96601000.0 in Q4 2025.

Alkermes (ALKS) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Income from Continuing Operations data on file, last reported at 66526000.0 in Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 395.82% year-over-year to 66526000.0 in Q1 2026; TTM through Mar 2026 was 199918000.0, a 53.29% decrease from a year earlier, with the FY2025 full-year figure at 288924000.0, down 34.99% from the prior year.
  • Income from Continuing Operations for Q1 2026 stood at 66526000.0, down from 96601000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ALKS reached as high as 279129000.0 in Q2 2023 and fell as low as 66526000.0 in Q1 2026.
  • Historically, Income from Continuing Operations has averaged 67277411.76 across 5 years, with a median of 87098000.0 in 2025.
  • Across the five-year window, Income from Continuing Operations tumbled 1374.79% in 2022 and surged 1026.23% in 2023, its largest moves.
  • Year by year, Income from Continuing Operations stood at 87716000.0 in 2022, then surged by 83.04% to 160554000.0 in 2023, then surged by 35.81% to 218049000.0 in 2024, then sank by 55.7% to 96601000.0 in 2025, then slumped by 168.87% to 66526000.0 in 2026.
  • Per Business Quant data, the three most recent Income from Continuing Operations figures were 66526000.0 in Q1 2026, 96601000.0 in Q4 2025, and 82745000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn -66.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -66.53 Mn
Dec 31, 2025 96.60 Mn
Sep 30, 2025 82.75 Mn
Jun 30, 2025 87.10 Mn
Mar 31, 2025 22.49 Mn
Dec 31, 2024 218.05 Mn
Sep 30, 2024 92.83 Mn
Jun 30, 2024 94.66 Mn
Mar 31, 2024 38.91 Mn
Dec 31, 2023 160.55 Mn
Sep 30, 2023 91.51 Mn
Jun 30, 2023 279.13 Mn
Mar 31, 2023 -12.03 Mn
Dec 31, 2022 87.72 Mn
Sep 30, 2022 -63.97 Mn
Jun 30, 2022 -30.14 Mn
Mar 31, 2022 -35.90 Mn
Dec 31, 2021 137.03 Mn
Sep 30, 2021 -28.99 Mn
Jun 30, 2021 2.36 Mn